NCT05522738 2024-01-08
Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Chinese PLA General Hospital
Phase 1/2 Unknown
Clinical Trials
3 trialsNCT05982834 2023-08-09
Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
Fudan University
Phase 1/2 Unknown
NCT05016869 2022-08-18
Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer
ChineseAMS
Phase 1/2 Unknown